NewLink nets $20M Ebola milestone from Merck

NewLink's ($NLNK) Ebola vaccine tie-up with Merck ($MRK) continues to pay off. The Iowa-based company has triggered a milestone payment from the pharma giant worth $20 million, it said last week, and it'll put the money back into its vaccine work for infectious diseases. Release

Suggested Articles

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.